IV Valproate Sodium for Prevention of Chronic Migraine

TAKE-HOME MESSAGE

The authors of this case series evaluated clinical outcomes for 13 patients with chronic refractory migraine treated with a 4-day course of daily intravenous infusions of 250-mg valproate. The patients selected for this case series were nonresponders or had contraindications to traditional medications such as dihydroergotamine and chlorpromazine. In all, 5 patients had improvements in headache severity during the infusion period. At 4 to 6 weeks’ follow-up, 9 patients had improvements in headache frequency, intensity, and/or medication use.